The search for safe and effective CAR-T targets in AML
Source
Blood cancer journal - ISSN 2044-5385-16:1 (2026) p.
CD19 CART-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1) : phase 1 results from a single-arm, multicentre, phase 1/2 study
Source
Lancet haematology - ISSN 2352-3026-13:9 (2026) p. 648-659
Inflammatory mechanisms in the AML bone marrow niche : from pathogenesis to therapy
Source
Cytokine and growth factor reviews - ISSN 1359-6101-91 (2026) p. 99-109
CD44 as a conserved biomarker and functional modulator of neuroinflammation in multiple sclerosis and beyond
Source
Molecular neurobiology - ISSN 0893-7648-63:1 (2026) p.
Persistent Campylobacter jejuni enterocolitis after CAR T-cell therapy in a patient with hypogammaglobulinemic follicular lymphoma
Source
ASM case reports - ISSN 2996-2684- (2026) p. 1-7
Proteomics in acute myeloid leukemia : current applications in precision medicine and targeted immunotherapy
Source
Technology in cancer research & treatment - ISSN 1533-0346-25 (2026) p.
Advances in ex vivo mRNA-based gene transfer for cell-based cancer immunotherapy
Source
Molecular therapy : Nucleic acids - ISSN 2162-2531-37 (2026) p.
Blood transcriptome bridges orthogonal immunotypes and gut microbiome enterotypes in humans
Source
Cell reports - ISSN 2211-1247-45:8 (2026) p.
CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine
Source
Frontiers in immunology - ISSN 1664-3224-17 (2026) p.
Mesenchymal stromal cells and neuroinflammation : a multimodal approach to neuroprotection and future therapeutic horizons
Source
Translational neurodegeneration - ISSN 2047-9158-15:1 (2026) p. 1-31